Mixed Data For Merck KGaA's Disease-Modifying OA Drug
German firm looking to partner sprifermin
Sprifermin could be the first drug to affect the underlying disease process in osteoarthritis but data show no significant improvement in symptoms.
You may also be interested in...
The German group believes its €2bn target of pipeline sales by 2022 is achievable. It is hoping for a healthy contribution from rare lung cancer drug tepotinib.
The Dutch biotech has signed off a sizeable series B fundraising to take its intranasal products to fight current and future viral outbreaks into the clinic.
The bosses of Bayer and Roche's pharmaceutical divisions – Stefan Oelrich and Bill Anderson – have called on governments in Europe to create a friendlier environment so that the sector and policymakers can continue to work better together post-pandemic.